A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.
We present the second case of a patient with platinum-refractory ovarian cancer who was treated safely with paclitaxel while on hemodialysis. Paclitaxel was administered at 175 mg/m2 as a 24-hour intravenous infusion on a nondialysis day. The patient tolerated this therapy well with minimal toxic reactions except for total alopecia and myelosuppression, which was unremarkable. Paclitaxel may be used in patients receiving long-term hemodialysis in the same dose schedule as in patients with normal renal function.